Patents by Inventor Abdolmohamad Rostami

Abdolmohamad Rostami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligodendrocyte-derived Extracellular Vesicles for Therapy of Multiple Sclerosis
    Publication number: 20220323506
    Abstract: In various aspects and embodiments the invention provides a method of treating multiple sclerosis in a subject in need thereof, the method comprising administering to the subject an effective amount of an oligodendrocyte-derived extracellular vesicle.
    Type: Application
    Filed: June 3, 2020
    Publication date: October 13, 2022
    Inventors: Abdolmohamad ROSTAMI, Giacomo CASELLA, Bogoljub CIRIC, Guang-Xian ZHANG
  • Use of Bowman Birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
    Patent number: 7255887
    Abstract: Provided is a use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissues are affected by the disease.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: August 14, 2007
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Abdolmohamad Rostami, Ann Kennedy
  • Use of bowman birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
    Patent number: 6767564
    Abstract: The present invention provides a non-toxic therapy and a novel use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissue is affected by the disease.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: July 27, 2004
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Abdolmohamad Rostami, Ann R. Kennedy
  • Use of Bowman Birk Inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
    Publication number: 20040142050
    Abstract: The present invention provides a non-toxic therapy and a novel use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissues is affected by the disease.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 22, 2004
    Inventors: Abdolmohamad Rostami, Ann R. Kennedy
  • Use of bowman birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
    Publication number: 20020127289
    Abstract: The present invention provides a non-toxic therapy and a novel use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissue is affected by the disease.
    Type: Application
    Filed: August 31, 2001
    Publication date: September 12, 2002
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Abdolmohamad Rostami, Ann R. Kennedy